Dr. Yinke Yang     


Dr. Yinke Yang , President of Shenzhen BioScien Pharmaceuticals and Hunan Yingzi Biotech Inc. , Professor at Hunan University and Visiting Professor at Shenzhen University . Dr. Yang received his Master degree in Pathophysiology from Hunan Medical University and his Doctor degree in Physiology from Central South University in China and Boston University in America . He had completed the training for postdoctoral fellow at Harvard Medical School. He worked as a research assistant professor at University of Pittsburgh Medical Center and as a senor research fellow at Harvard Medical School. He has over 20 years experience in cell physiological study. He had been working at Beth Israel Deaconess Medical Center , Brigham and Women’s Hospital , Harvard Medical School for many years . His researches involve in new drug clinical testing and the feasibility . Especially , he has original views on studying stem cell proliferation differentiation and cell-base assay for novel product characterization . Dr. Yang had received Excellent Trainee Abstract Award from American Heart Association (AHA) , Young Investigator Award from Heart Failure Society of America , Melvin L . Marcus Young Investigator Award of AHA in America , and Science and Technology Advance Award of Ministry of Public Health , Science and Technology Advance Award from Hunan Province , Excellent Research Paper from Chinese Association of Physiology , China . He has published more than 40 scientific papers and had been granted 4 patents . Dr. Yang returned to China in 2012 and has invested and established two companies : Shenzhen BioScien Pharmaceutical located at Shenzhen Overseas Chinese High-Tech Venture Park (Longgang) and Hunan Yingzi Biotech Inc . in Lu Valley,Changsha . He has successfully created a platform for the development of innovative medicine . The current projects are including Novel Anti-Cancer Peptide , New Anti-Carcinoma Target Drug , New Immunosuppressant . These products are in different stages of pre-clinical and phase II . Breakthroughs are expected in the near future and hopefully the new products will early enter the market so that they can benefit the people .